|
2018 Conference Publication Early clinical predictors of severe MSMalpas, C., Sharmin, S., Horakova, D., Havrdova, E. K., Trojano, M., Izquierdo, G., Bergamaschi, R., Sola, P., Ferraro, D., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Grammond, P., Grand'Maison, F., Ozakbas, S., Van Pesch, V., Granella, F., Hupperts, R., Pucci, E., Boz, C., Iuliano, G., Sidhom, Y., Gouider, R., Spitaleri, D., Butzkueven, H., Soysal, A., Petersen, T., Verheul, F. ... Kalincik, T. (2018). Early clinical predictors of severe MS. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registrySpelman, T., Harvrdova, E. K., Horakova, D., Izquierdo, G., Kalincik, T., Lugaresi, A., Onofrj, M., Duquette, P., Girard, M., Prat, A., Grammond, P., Grand'Maison, F., Granella, F., Lechner-Scott, J., Sola, P., Ferrero, D., Sa, M. J., Terzi, M., Ozakbas, S., Van Pesch, V., Van Wijmeersch, B., Boz, C., Karabudak, R., Cartechini, E., McCombe, P. and Butzkueven, H. (2018). Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remitting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry. 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin Germany, Oct 10-12, 2018. LONDON: SAGE PUBLICATIONS LTD. |
|
2018 Conference Publication Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.p6.366 |
|
2018 Conference Publication Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase RegistryKister, Ilya, Bacon, Tamar, Shaygannejad, Vahid, Havrdova, Eva, Alroughani, Raed, Terzi, Murat, Altintas, Ayse, Hor, Jyh Yung, Al-Harbi, Talal, Boz, Cavit, Bergamaschi, Roberto, Ozakbas, Serkan, Ferraro, Diana, Fragoso, Yara, Laureys, Guy, Soysal, Aysun, Majdinassab, Nastaran, Onofrj, Marco, Pucci, Eugenio, Vucic, Ostoja (Steve), Slee, Mark, Lechner-Scott, Jeannette, Rojas, Juan Ignacio, Burgos, Marcos, Castillo Trivino, Tamara, Reid, Allyson, Rimler, Zoe, McCombe, Pamela, Granella, Franco ... Butzkueven, Helmut (2018). Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles Ca, Apr 21-27, 2018. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2018 Conference Publication Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jérôme, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.p6.376 |
|
2018 Conference Publication Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)Van Wijmeersch, B., Vermersch, P., Boyko, A., de Seze, J., Hartung, H. -P., Havrdova, E. Kubala, Inshasi, J. Said, McCombe, P., Montalban, X., Pozzili, C., Melanson, M., Daizadeh, N., Rodriguez, C. and Selmaj, K. (2018). Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study). 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, 16-19 June 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2018 Conference Publication Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)Inshasi, Jihad Said, Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Vermersch, Patrick and Margolin, David H. (2018). Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study). 3rd Congress of Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS), Dubai, UAE, 24-25 November 2017 . London, United Kingdom : Sage Publications. |
|
2018 Conference Publication Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study)Steingo, Brian, Oreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Van Wijmeersch, Bart, Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Vermersch, Patrick (2018). Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2018 Conference Publication Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)McCombe, Pamela, Boyko, Alexey N., DeSeze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Vermersch, Patrick, Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Annual Scientific Meeting of the Australian-and-New Zealand-Association-of-Neurologists (ANZAN), Darwin Australia, May 29 - June 1 2018. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2018-ANZAN.43 |
|
2017 Conference Publication Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I)Singer, Barry, Coles, Alasdair J., Boyko, Alexey N., Cohen, Jeffrey A., De Seze, Jérôme, Fox, Edward J., Havrdova, Eva, Hartung, Hans-Peter, Inshasi, Jihad Said, McCombe, Pamela, Selmaj, Krzysztof W., Vermersch, Patrick, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio and Montalban, Xavier (2017). Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I). AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.s24.005 |
|
2017 Conference Publication Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-upOreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Steingo, Brian, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Vermersch, Patrick and on behalf of the CARE-MS I and CAMMS03409 Investigators (2017). Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up. AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.p5.360 |
|
2017 Conference Publication Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development programRog, D., Oh, J., Chambers, C., Hellwig, K., McCombe, P., Otero, S., Margolin, D. H., Daizadeh, N. and Compston, D. A. S. (2017). Pregnancy outcomes in patients with RRMS treated with alemtuzumab from the clinical development program. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404 |
|
2017 Conference Publication Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control ParticipantsSteyn, Frederik J., Restuadi, Restuadi, Ioannides, Zara, Ngo, Shyuan T., McRae, Allan, Wray, Naomi R., Henderson, Robert and McCombe, Pamela (2017). Comparison of Faecal Microbe Diversity Between Motor Neurone Disease (Mnd) and Control Participants. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: BMJ. doi: 10.1136/jnnp-2017-316074.81 |
|
2017 Conference Publication Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosisMerkel, B., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Sola, P., Ferraro, D., Grammond, P., Hupperts, R., Bergamaschi, R., Alroughani, R., Boz, C., Terzi, M., Pucci, E., Van Pesch, V., Grand'Maison, F., Fernandez-Bolanos, R., Lechner-Scott, J., Spitaleri, D., Shaygannejad, V., Iuliano, G., Granella, F., Solaro, C. ... Kalincik, T. (2017). Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283 |
|
2017 Conference Publication Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple SclerosisMerkel, Bernd, Jokubaitis, Vilija, Spelman, Tim, Lechner-Scott, Jeannette, McCombe, Pamela, Slee, Mark, Vucic, Steve, Skibina, Olga, Barnett, Michael, Hodgkinson, Suzanne, Butzkueven, Helmut and Kalincik, Tomas (2017). Timing of High-Efficacy Disease Modifying Therapies for Relapsing-Remitting Multiple Sclerosis. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, May 09-12, 2017. LONDON: BMJ PUBLISHING GROUP. doi: 10.1136/jnnp-2017-316074.16 |
|
2017 Conference Publication Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysisJokubaitis, V. G., Havrdova, E., Horakova, D., Izquierdo, G., Kalincik, T., van der Walt, A., Nguyen, A. -L., Terzi, M., Alroughani, R., Duquette, P., Girard, M., Prat, A., Boz, C., Sola, P., Lugaresi, A., Lechner-Scott, J., Barnett, M., Grand'Maison, F., Grammond, P., Ramo, C., Turkoglu, R., McCombe, P., Hupperts, R., Bolanos, R. Fernandez, Pucci, E., Trojano, M., Granella, F., Spitaleri, D., Van Pesch, V. ... Butzkueven, H. (2017). Pregnancy incidence and therapy exposure in relapsing forms of MS: a 12-year retrospective multicentre analysis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731404 |
|
2017 Conference Publication Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registrySpelman, T., Schulz, M., Arora, B., Chung, E., Juneja, P., Walker, R., Verhaeghe, S., Butzkueven, H., Hodgkinson, S., Lechner-Scott, J., McCombe, P., Slee, M., Butler, E., Barnett, M., Skibina, O., Vucic, S., Macdonell, R., Shuey, N., Taylor, B. and Broadley, S. (2017). Persistence to fingolimod compared with other disease modifying therapies in the Australian real-world setting using the MS base registry. 7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. |
|
2017 Conference Publication The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosisBrown, J. W. L., Lugaresi, A., Horakova, D., Havrdova, E., Jokubaitis, V., Lechner-Scott, J., Trojano, M., Min, M., Shaw, C., Shuey, N., Slee, M., Mccombe, P., Van Pesch, V., Van Wijmeersch, B., Prevost, J., Moore, F., Prat, A., Girard, M., Duquette, P., Ayrignac, X., Sempere, A. Perez, Sanchez-Menoyo, J. L., Ramo-Tello, C., Csepany, T., Hutchinson, M., De Luca, G., Bergamaschi, R., Granella, F., Curti, E. ... Kalincik, T. (2017). The risk of relapse following on-treatment clinically silent lesions in patients with relapsing-remitting multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517733228 |
|
2017 Conference Publication Gelsolin, clusterin and Cd5L are the potential plasma biomarkers of amyotrophic lateral sclerosis with and without cognitive impairmentXu, Zhouwei, Lee, Aven, Henderson, Robert and McCombe, Pamela (2017). Gelsolin, clusterin and Cd5L are the potential plasma biomarkers of amyotrophic lateral sclerosis with and without cognitive impairment. Annual Scientific Meeting of the Australian-and-New-Zealand-Association-of-Neurologists (ANZAN), Gold Coast, Australia, 9-12 May 2017. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2017-316074.34 |
